Govt to ban semaglutide compounding from October amid patient safety fears
A provider of compounded semaglutide said patient treatment would be disrupted.
The TGA is banning pharmacists from compounding semaglutide and other GLP-1 receptor agonists, starting 1 October.
About 20,000 patients are currently using compounded semaglutide for weight loss, according to Minister for Health and Aged Care Mark Butler.
It follows a global shortage of Novo Nordisk’s Ozempic, which prompted GP telehealth sites such as Eucalyptus to start prescribing locally compounded semaglutide from late last year.
But on Tuesday, Mr Butler said the government planned to remove GLP-1 receptor agonists from the list of drugs that pharmacists could compound.
